Anti-CD19 Chimeric Antigen Receptor Modified T-cell (CAR-T) Therapy for Treatment of B-cell Hematological Malignancies

NCT06462248 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Lymphoma, Nonhodgkin
Leukemia, Lymphocytic

Interventions

DRUG: CUCART19

Sponsor

Chi Kong Li

Collaborators

[object Object]